Trial reportInflammopharmacology2026
Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study.
Trial report in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGout is a chronic inflammatory disorder characterized by recurrent painful flares and elevated uric acid levels. Metformin possesses anti-inflammatory and metabolic regulatory properties that may offer additional benefit when combined with febuxostat.
aimTo evaluate the therapeutic efficacy of adding metformin to febuxostat in patients with gout.
methodsA randomized, double-blinded, controlled clinical trial was conducted on 60 gout patients and were randomly assigned to receive either febuxostat and placebo (control group, n = 30) or febuxostat plus metformin (metformin group, n = 30). Clinical assessment included the visual analogue scale (VAS) for pain, while laboratory evaluation comprised serum uric acid, tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and free fatty acids. All biomarkers except free fatty acids were measured using ELISA; free fatty acids were determined colorimetrically. Lipid profile parameters were also recorded. Adverse effects were monitored in both groups.
resultsBoth groups showed significant reduction in all measured markers. The addition of metformin resulted in significantly greater reductions in VAS scores (- 33.3%), TNF-α (- 45.3%), IL-1β (- 12.3%), and uric acid levels (- 12.5%) compared with control group (all p < 0.05). The metformin group also demonstrated a significant decrease in free fatty acids (- 6.2%) with p = 0.032 and triglycerides (- 10.6%) with p = 0.002. No significant differences were observed regarding the frequency of drug-related side effects (all p > 0.05).
conclusionMetformin as an adjuvant to febuxostat provides superior improvement in pain, inflammatory markers, uric acid levels, and metabolic parameters in gout patients, without increasing adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.